CD5+ follicular lymphoma: A clinicopathologic study of three cases

American Journal of Clinical Pathology

Volumn 118, Issue 4, 2002, Pages 589-598

  Barry, Todd S ^a   Jaffe, Elaine S ^a   Kingma, Douglas W ^a   Martin, Alvin W ^b   Sorbara, Lynn ^a   Raffeld, Mark ^a   Pittaluga, Stefania ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

bcl 2; CD5; Flow cytometry; Follicular lymphoma; IgH gene rearrangement; Immunohistochemistry; t(14; 18)

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD5 ANTIGEN; PROTEIN BCL 2; PROTEIN BCL 6; DNA; DNA BINDING PROTEIN; IMMUNOGLOBULIN LIGHT CHAIN; MEMBRANE METALLOENDOPEPTIDASE; ONCOPROTEIN; TRANSCRIPTION FACTOR;

ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CASE REPORT; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; HISTOLOGY; HUMAN; PRIORITY JOURNAL; THYMOCYTE; ADULT; CHROMOSOME 14; CHROMOSOME 18; FEMALE; GENE REARRANGEMENT; GENE TRANSLOCATION; GENETICS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; ANTIGENS, CD5; B-LYMPHOCYTES; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 18; DNA, NEOPLASM; DNA-BINDING PROTEINS; FEMALE; FLOW CYTOMETRY; GENE REARRANGEMENT, B-LYMPHOCYTE, HEAVY CHAIN; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEPRILYSIN; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-BCL-6; TRANSCRIPTION FACTORS; TRANSLOCATION, GENETIC;

EID: 0036780707     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/4KEH-AGY7-UT5H-41XJ     Document Type: Article

References (46)

1. Greiner TC, Medeiros LJ, Jaffe ES. Non-Hodgkin's lymphoma. Cancer. 1995;75:370-380.
2. Medeiros LJ, Carr J. Overview of the role of molecular methods in the diagnosis of malignant lymphomas. Arch Pathol Lab Med. 1999;123:1189-1207.
3. Stamatopoulos K, Kosmas C, Belessi C, et al. Molecular insights into the immunopathogenesis of follicular lymphoma. Immunol Today. 2000;21:298-305.
4. Dogan A, Bagdi E, Munson P, et al. CD10 and bcl-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol. 2000;24:846-852.
5. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol. 2000;13:193-207.
6. Cossman J, Neckers LM, Hsu S, et al. Low-grade lymphomas: expression of developmantally regulated B-cell antigens. Am J Pathol. 1984;115:117-124.
7. Harris NL, Nadler LM, Bhan AK. Immunohistologic characterization of two malignant lymphomas of germinal center type (centroblastic/centrocytic and centrocytic) with monoclonal antibodies: follicular and diffuse lymphomas of small-cleaved-cell type are related but distinct entities. Am J Pathol. 1984;117:262-272.
8. Al Saati T, Laurent G, Caveriviere P, et al. Reactivity of Leu 1 and T101 monoclonal antibodies with B cell lymphomas (correlations with other immunological markers). Clin Exp Immunol. 1984;58:631-638.
9. Dorfman DM, Shahsafaei A. Usefulness of a new CD5 antibody for the diagnosis of T-cell and B-cell lymphoproliferative disorders in paraffin sections. Mod Pathol. 1997;10:859-863.
10. de Leon ED, Alkan S, Huang JC, et al. Usefulness of an immunohistochemical panel in paraffin-embedded tissues for the differentiation of B-cell non-Hodgkin's lymphomas of small lymphocytes. Mod Pathol. 1998;11:1046-1051.
11. Lydyard PM, Jewell AP, Jamin C, et al. CD5 B cells and B-cell malignancies. Curr Opin Hematol. 1999;6:30-36.
12. Youinou P, Jamin C, Lydyard PM. CD5 expression in human B-cell populations. Immunol Today. 1999;20:312-316.
13. Spertini F, Stohl W, Ramesh N, et al. Induction of human T cell proliferation by a monoclonal antibody to CD5. J Immunol. 1991;146:47-52.
14. Tarakhovsky A, Kanner SB, Hombach J, et al. A role for CD5 in TCR-mediated signal transduction and thymocyte selection. Science. 1995;269:535-537.
15. Lankester AC, van Schijndel GM, Cordell JL, et al. CD5 is associated with the human B cell antigen receptor complex. Eur J Immunol. 1994;24:812-816.
16. Haughton G, Arnold LW, Whitmore AC, et al. B-1 cells are made, not born. Immunol Today. 1993;14:84-91.
17. Sundeen JT, Longo DL, Jaffe ES. CD5 expression in B-cell small lymphocytic malignancies: correlations with clinical presentation and sites of disease. Am J Surg Pathol. 1992;16:130-137.
18. Banks PM, Chan J, Cleary ML, et al. Mantle cell lymphoma: a proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol. 1992;16:637-640.
19. Burns BF, Wamke RA, Doggett RS, et al. Expression of a T-cell antigen (Leu-1) by B-cell lymphomas. Am J Pathol. 1983;113:165-171.
20. Matolcsy A, Chadburn A, Knowles DM. De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct. Am J Pathol. 1995;147:207-216.
21. Ferry JA, Yang WI, Zukerberg LR, et al. CD5+ extranodal marginal zone B-cell (MALT) lymphoma: a low grade neoplasm with a propensity for bone marrow involvement and relapse. Am J Clin Pathol. 1996;105:31-37.
22. Lin CW, O'Brien S, Faber J, et al. De novo CD5+ Burkitt lymphoma/leukemia. Am J Clin Pathol. 1999;112:828-835.
23. Khalidi HS, Brynes RK, Browne P, et al. Intravascular large B-cell lymphoma: the CD5 antigen is expressed by a subset of cases. Mod Pathol. 1998;11:983-988.
24. Knowles DM, Halper JP, Azzo W, et al. Reactivity of monoclonal antibodies Leu 1 and OKT1 with malignant human lymphoid cells: correlation with conventional cell markers. Cancer. 1983;52:1369-1377.
25. Schuurman HJ, van Baarlen J, Huppes W, et al. Immunophenotyping of non-Hodgkin's lymphoma: lack of correlation between immunophenotype and cell morphology. Am J Pathol. 1987;129:140-151.
26. Schwonzen M, Pohl C, Steinmetz T, et al. Immunophenotyping of low-grade B-cell lymphoma in blood and bone marrow: poor correlation between immunophenotype and cytological/histological classification. Br J Haematol. 1993;83:232-239.
27. Tiesinga JJ, Wu CD, Inghirami G. CD5+ follicle center lymphoma. Am J Clin Pathol. 2000;114:912-921.
28. Wilson WH, Teruya-Feldstein J, Fest T, et al. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood. 1997;89:601-609.
29. Ramasamy I, Brisco M, Morley A. Improved PCR method for detecting monoclonal immunoglobulin heavy chain rearrangement in B cell neoplasms. J Clin Pathol. 1992;45:770-775.
30. Trainor KJ, Brisco MJ, Story CJ, et al. Monoclonality in B-lymphoproliferative disorders detected at the DNA level. Blood. 1990;75:2220-2222.
31. Elenitoba-Johnson KSJ, Kumar S, Lim MS, et al. Marginal zone B-cell lymphoma with monocytoid B-cell lymphocytes in pediatric patients without immunodeficiency. Am J Clin Pathol. 1997;107:92-98.
32. Stetler-Stevenson M, Raffeld M, Cohen P, et al. Detection of occult follicular lymphoma by specific DNA amplification. Blood. 1988;72:1822-1825.
33. Ben-Ezra JM, Kornstein MJ. Antibody NCL-CD5 fails to detect neoplastic CD5+ cells in paraffin sections. Am J Clin Pathol. 1996;106:370-373.
34. Salhany KE, van de Rijn M, Montone KT, et al. CD5 immunostaining of lymphoid neoplasms in paraffin sections [letter]. Am J Clin Pathol. 1997;107:496-497.
35. Watson P, Wood KM, Lodge A, et al. Monoclonal antibodies recognizing CD5, CD10 and CD23 in formalin-fixed, paraffin-embedded tissue: production and assessment of their value in the diagnosis of small B-cell lymphoma. Histopathology. 2000;36:145-150.
36. Yamaguchi M, Ohno T, Oka K, et al. De novo CD5-positive diffuse large B-cell lymphoma: clinical characteristics and therapeutic outcome. Br J Haematol. 1999;105:1133-1139.
37. Ballesteros E, Osborne BM, Matsushima AY. CD5+ low-grade marginal zone B-cell lymphomas with localized presentation. Am J Surg Pathol. 1998;22:201-207.
38. Kaleem Z, White G, Vollmer RT. Critical analysis and diagnostic usefulness of limited immunophenotyping of B-cell non-Hodgkin lymphomas by flow cytometry. Am J Clin Pathol. 2001;115:136-142.
39. DiGiuseppe JA, Borowitz MJ. Clinical utility of flow cytometry in the chronic lymphoid leukemias. Semin Oncol. 1998;25:6-10.
40. Garcia DP, Rooney MT, Ahmad E, et al. Diagnostic usefulness of CD23 and FMC-7 antigen expression in B-cell lymphoma classification. Am J Clin Pathol. 2001;115:258-265.
41. Pittaluga S, Wlodarska I, Stul MS, et al. Mantle cell lymphoma: a clinicopathological study of 55 cases. Histopathology. 1995;26:17-24.
42. Lai R, Weiss LM, Chang KL, et al. Frequency of CD43 expression in non-Hodgkin lymphoma: a survey of 742 cases and further characterization of rare CD43+ follicular lymphomas. Am J Clin Pathol. 1999;111:488-494.
43. Falini B, Fizzotti M, Pileri S, et al. bcl-6 protein expression in normal and neoplastic lymphoid tissues. Ann Oncol. 1997;8:101-104.
44. Gaulard P, d'Agay MF, Peuchmaur M, et al. Expression of the bcl-2 gene product in follicular lymphoma. Am J Pathol. 1992;140:1089-1095.
45. Horsman DE, Gascoyne RD, Coupland RW, et al. Comparison of cytogenetic analysis, Southern analysis, and polymerase chain reaction for the detection of t(14; 18) in follicular lymphoma. Am J Clin Pathol 1995;103:472-478.
46. Harada S, Suzuki R, Uehira K, et al. Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5- with CD10+ groups may constitute clinically relevant subtypes. Leukemia. 1999;13:1441-1447.